

Search worldwide, life-sciences literature

Search

[Advanced Search](#)[Coronavirus articles and preprints](#) Search examples: "breast cancer" Smith J[Recent history](#)[Saved searches](#)

## Immunogenic "subunit" of the ICRC antileprosy vaccine.

Chirmule NB, Chaturvedi RM, Deo MG

[Author information ▾](#)[Abstract](#)

International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, 01 Mar 1988, 56(1):27-35

PMID: 3131465

[View key terms](#)[Citations & impact](#)[Similar Articles](#)

Share this article

[Get citation](#) [Claim to ORCID](#)

### Abstract

The administration of a vaccine containing ICRC bacilli, which is currently undergoing clinical trials in India, induces persistent lepromin conversion in lepromatous leprosy (LL) patients and lepromin-negative healthy subjects, with "upgrading" of tissue response in the former. A sonicate of ICRC bacilli, when subjected to gel-filtration chromatography using high-pressure liquid chromatography (HPLC), yields a high molecular weight glycolipoprotein (PP-I) with an apparent molecular weight of 10(6) daltons. PP-I, which brings about lepromin conversion in lepromin-negative healthy subjects, is a major immunogen of the organism, and carries epitopes for both B and T cells. A similar high molecular weight glycolipoprotein (PP-I Mycobacterium leprae) has been isolated from the sonicate of *M. leprae*. The two PP-I fractions exhibit a close antigenic relatedness at both B- and T-cell levels. However, they differ in their chemical composition and carry different charges. PP-I of ICRC is not only a good immunogen. Its high lipid content provides the necessary built-in adjuvant that would make it a good candidate for a "subunit" antileprosy vaccine. Also, since it carries epitopes for both B and T cells, PP-I ICRC could be used for "molecular engineering" to obtain molecules which selectively stimulate T-cell immunity which is the dominant host defense against *M. leprae*.

### Citations & impact

### Similar Articles

### About

[About Europe PMC](#)  
[Funders](#)  
[Joining Europe PMC](#)  
[Governance](#)  
[Roadmap](#)  
[Outreach](#)

### Tools

[Tools overview](#)  
[ORCID article claiming](#)  
[Journal list](#)  
[Grant finder](#)  
[External links service](#)  
[RSS feeds](#)  
[Annotations](#)  
[Annotations submission service](#)

### Developers

[Developer resources](#)  
[Articles RESTful API](#)  
[Grants RESTful API](#)  
[API use cases](#)  
[SOAP web service](#)  
[Annotations API](#)  
[OAI service](#)  
[Bulk downloads](#)  
[Developers Forum](#)

### Help

[Help using Europe PMC](#)  
[Search syntax reference](#)  
[Contact us](#)

### Contact us

[Helpdesk](#)  
[Feedback](#)  
[Twitter](#)  
[Blog](#)  
[Tech blog](#)  
[Developer forum](#)

Let us know how we are doing.

[Give feedback](#)

Europe PMC is part of the ELIXIR infrastructure

Europe PMC is an ELIXIR Core Data Resource [Learn more >](#)

Europe PMC is a service of the Europe PMC Funders' Group, in partnership with the European Bioinformatics Institute; and in cooperation with the National Center for Biotechnology Information at the U.S. National Library of Medicine (NCBI); includes content provided to the PMC International archive by participating publishers.



This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our [privacy notice](#) and [cookie policy](#).

[I agree, dismiss this banner](#)

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our [privacy notice](#) and [cookie policy](#).

[I agree, dismiss this banner](#)